Breast cancer trial halted after just 2 patients enrolled
NCT ID NCT02688803
First seen Jun 27, 2026 · Last updated Jun 27, 2026
Summary
This study aimed to test a simpler consent process to compare three standard chemotherapy regimens for triple-negative breast cancer. Only 2 participants enrolled before the trial was terminated early, so it could not determine which treatment works best. The main goal was to see if this new consent model was feasible, not to find a cure.
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
Active substance
chemotherapy (doxorubicin, cyclophosphamide, paclitaxel, 5-FU, epirubicin, docetaxel)
What this could lead to
If successful, this approach could make it easier to compare standard treatments in real-world settings, helping doctors choose the best chemotherapy for triple-negative breast cancer.
What could go wrong
The trial was terminated early with only 2 participants, so it did not gather enough data to draw meaningful conclusions. The results may not apply to broader populations.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for BREAST CANCER are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Locations
-
The Ottawa Hospital Cancer Centre
Ottawa, Ontario, K2H 8L6, Canada